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Summary Testosterone-induced DNA synthesis in cultured rat ventral prostate was used to compare the
direct effects of EstracytR and EmcytR with that of their metabolite, estramustine, and their carrier-hormone,
oestradiol-17/ on prostatic growth. In serum-supplemented medium (5-20% FCS), all the compounds were
equally effective in suppressing testosterone stimulated DNA synthesis which was reduced by between 40-
50%, whereas in serum-free medium the estramustine compounds were consistently less effective than
oestradiol-17,B. In the presence of 4 x 10 -9M testosterone in serum-free medium, stimulated DNA synthesis
was reduced by 15-30% following incubation with 4 x 10-7 M of EstracytR, EmcytR and estramustine and by
60% with 4 x 10-7 M oestradiol-17f3. Thus, none of the estramustine compounds appear to offer any selective
advantage over that of oestradiol-17/1 in suppressing prostatic DNA synthesis at the target tissue level.
Prostatic cancer is the most common malignancy of the male
urogenital tract and a leading cause of death due to cancer
in aging men (Chisholm, 1981; Flanders, 1984). As con-
ventional oestrogen therapy for prostatic cancer is not
curative, several new drugs have recently been developed
in an attempt to enhance tumour selectivity of chemo-
therapeutic agents and thereby improve the clinical manage-
ment of prostatic cancer patients. Among these, the
hormone-cytotoxic agent EstracytR (estramustine phosphate;
EmCytR, estramustine phosphate disodium) has been
extensively investigated for use in the treatment of prostatic
cancer (Jonsson & Hogberg, 1971; Nilsson & Jonsson, 1977;
Edsmyr et al., 1982; Hoisaeter & Bakke, 1983; Murphy et
al., 1983; Walzer et al., 1984). The rationale for Estracyt
therapy is based on the concept that the hormonal moiety of
the drug complex, oestradiol-17/1, would impart tissue
specificity by interacting with steroid hormone receptors in
the prostate and thus result in a selective accumulation of
the alkylating agent, a nor-nitrogen mustard, within the
target tissue. Yet, despite both clinical and experimental
investigations, the mechanism of action of Estracyt remains
unknown (Tew, 1983; Hoisaeter, 1984).
In both the rat (Plym-Forshell & Nilsson, 1974; Hoisaeter,
1976a, 1977; Hoisaeter & Bakke, 1983) and man (Plym-
Forshell et al., 1976; Sandberg, 1983), Estracyt is rapidly
dephosphorylated to yield estramustine and its dehydro-
genated counterpart, estromustine. These metabolites are
selectively retained in the prostate by interactions with
estramustine binding protein (Forsgren et al., 1979, 1981;
Bjork et al., 1982) and subsequent intracellular hydrolysis of
these compounds slowly liberates free nitrogen mustard and
oestrogen moieties. However, the question remains whether
the antiprostatic actions of Estracyt are mediated by the
oestrogen moiety, the nitrogen mustard moiety or the intact
drug complex itself.
While in vivo studies have shown that Estracyt is a more
potent inhibitor of rat prostatic DNA synthesis than either
its hormone or cytostatic parts (Hoisaeter, 1976b, 1977),
such comparisons are limited by the extensive metabolism of
Estracyt in vivo. Thus, in the present study, an in vitro model
of induced DNA synthesis in cultured rat ventral prostate
(Mistry et al., 1982; Buchanan & Riches, 1985, 1986) was
used to compare the direct effects of Estracyt, Emcyt,
estramustine and oestradiol-173 on prostatic growth.
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Materials and methods
Organ culture
Ventral prostate from young adult Wistar rats (4-6 months
old) was maintained in serum free and serum-supplemented
(5, 10 or 20% foetal calf serum) organ culture for 4 days
(Riches et al., 1976; Mistry et al., 1982; Buchanan & Riches,
1985, 1986). Explants of approximately 2mm3 were prepared
with 16 explants per treatment group.
Additives
Unless otherwise stated, testosterone was added alone or in
combination with Estracyt (LS 299), Emcyt (LS 299Z),
estramustine (LS 275) or oestradiol-17# on day 0 of the
culture period and replenished following the medium change
on day 2. The steroids were first dissolved in absolute
alcohol and then diluted in Waymouths medium to the
desired final concentration. Control cultures were maintained
in medium only or received an equal volume of the alcohol
diluent. The estramustine compounds (LS 299, LS 299Z, LS
275) were a generous gift of AKTIEBOLAGET LEO
Research Laboratories, Helsingborg, Sweden).
125lododeo.vyuridine (I UdR) uptake
During the final 24h of the culture period, each culture was
labelled with 37KBq (ljCi) of '25lododeoxyuridine (I-UdR:
specific activity 185 GBq mg- ', Amersham) as previously
described (Mistry et al., 1982). The explants were then fixed
in Bouins fluid, washed in 70% alcohol and weighed (Riches
et al., 1976).
I-UdR uptake (cpmmg- tissue) was monitored in a
Minigamma counter and the results expressed as a Stimu-
lation Index such that the testosterone only supplemented
control cultures equalled 1.0. In the cultures supplemented
with foetal calf serum and testosterone, uptakes are
expressed relative to 0% FCS and testosterone addition. All
the uptakes are plotted as mean +s.e. and represent the
pooled results from 3 replicate experiments. Following the
determination of I-UdR uptake, the explants were processed
for routine light microscopy.
Data analyjsis
In each experiment, 16 explants were randomly allocated per
treatment group and comprised 4 replicate cultures. Data are
presented as the mean +s.e. from n> 3 experiments. Data
were analyzed by analysis of variance and Duncan's multiple
range test (P<0.01).
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Results
EI/ects ol serunm
I-UtIR uptake Figure 1 illustrates the effects of 4 x 10-I M
Extracyt, estramustine and oestradiol- 17/3 on the pro-
liferative response of rat ventral prostate to 4 x 10-6M
testosterone following four days of organ culture in medium
containing 0, 5, 10 or 20% foetal calf serum. I-UdR uptakes
are normalised to the 0% FCS and testosterone-stimulated
measurements. In serum-free medium, only oestradiol-17/3
significantly (P<0.01) inhibited the proliferative response to
testosterone. Estracyt was not significantly inhibitory in
serum free cultures (P>0.05). However, in serum supple-
mented media, the estramustine compounds and oestradiol-
17/3 all reduced the testosterone response to the level of the
unstimulated controls.
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Figure 1 Effects of 4 x 10-I Estracyt (LS 299), estramustine (LS
275) and oestradiol-17tj (E2-17fl on 4 x 10-6 M testosterone
stimulated I-UdR uptake in serum-free and serum-supplemented
(5, 10, 20% FCS) cultures of rat ventral prostate. Testosterone-
free control cultures are represented by C and testosterone
supplemented control cultures by * (mean + s.e.: 16
explants/treatment group, 3 separate experiments).
Histology Normal rat ventral prostate consists of tubulo-
alveolar glands which are lined by a single layer of columnar
epithelial cells (Figure 2A). Cultures maintained in serum-
supplemented medium without testosterone underwent
epithelial atrophy, whereas the addition of 4x 10x6M
testosterone maintained the height and secretory activity of
the alveolar epithelium and promoted epithelial cell prolifera-
tion (Figure 2B). Similar cultures treated with testosterone
and 4 x 10- I M Estracyt (Figure 2C) or estramustine exhibited
extensive necrosis of the alveolar epithelium, whereas
treatment with 4x 10- M oestradiol-17/ caused marked
epithelial atrophy (Figure 2D).
In serum-free medium, cultures maintained in the absence
of testosterone were atrophic, whereas supplementation with
4 x 10-6 M testosterone preserved the normal morphology
and secretory activity of the epithelium (Figure 3A). Similar
cultures treated with 4 x 10-6 M testosterone and 4 x 10 -S M
Estracyt (Figure 3B) or estramustine also exhibited well-
maintained alveolar epithelium. In contrast, treatment with
4 x 10 M oestradiol-17/3 was cytotoxic causing widespread
necrosis of the alveolar epithelium and fibromuscular stroma
(Figure 3C).
Figure 2 Alveoli in a fresh fixed specimen and in explants of
young adult rat ventral prostate cultured for 4 days in medium
containing 5% foetal calf serum H & E staining. (A) Control
(uncultured) section showing the columnar epithelium of rat
ventral prostate ( x 500). (B) Explant treated with 4 x 10-6 M
testosterone showing actively secreting columnar epithelium
( x 500). (C) Explant treated with 4 x 10- M testosterone and
4 x O- M Extracyt showing marked degeneration and necrosis
of the secretory epithelium (x 500). (D) Explant treated with
4x 10-6 M testosterone and 4x 1O- M oestradiol-17f1 showing
dilated alveoli and epithelial atrophy ( x 500).
Effects ofconcentration
I-UdR uptake The effects of 4x 10-9, 4x 10 and
4 x 10 - M Estracyt, Emcyt, estramustine and oestradiol- 17,B
on the proliferative response of rat ventral prostate to
4 x 10-7M testosterone following four days of culture in
serum-free medium are shown in Figure 4. At 4 x 10 -9 and
4 x 10-7 M, oestradiol-17,B significantly (P<0.01) reduced the
testosterone effect and was markedly inhibitory (P<0.01) at
4 x 1O-M. In contrast, the estramustine compounds were
consistently less effective than oestradiol-17/ at all
concentrations used.
Using the same procedure, Figure 5 demonstrates the
effects of 4 x 10 -9, 4 x 10- 7 and 4 x 10 5M Estracyt, Emeyt,
estramustine and oestradiol-17/B on the proliferative response
to 4 x 10 -9M testosterone, which is the minimum dose of
testosterone for maximum stimulation of I-UdR uptake in
serum-free cultures of rat ventral prostate (Mistry et al.,
1982). Treatment with 4 x 10-9 and 4 x 10 M oestradiol-
17(3 reduced the testosterone response to the level of the
testosterone-free controls (P <0.01), whereas equimolar
concentrations of the estramustine compounds were less
effective. At 4x1-0M, Estracyt, Emcyt, and estramustine
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Figure 4 Effects of Estracyt (LS 299), Emcyt (LS 299Z),
estramustine (LS 275) and oestradiol-17,B (E,-177f) on 4 x 10-7M
testosterone stimulated 1-UdR uptake in serum free cultures of
rat ventral prostate. Testosterone-free control cultures are
represented by *, medium only, and CI, medium containing the
alcohol diluent (mean + s.e.; 16 explants/treatment group, 3
separate experiments). Dotted line indicates mean + s.e. of
stimulation index of testosterone only supplemented cultures.
Figure 3 Alveoli in explants of young adult rat ventral prostate
cultured for 4 days in serum free-medium. H & E staining. (A)
Explant treated with 4 x 10 6 M testosterone showing actively
secreting columnar epithelium (x 500). (B) Explant treated with
4 x 10 -6 M testosterone and 4 x 10-5 Estracyt showing well-
maintained alveolar epithelium ( x 500). (C) Explant treated with
4 x 1O-6 M testosterone and 4 x 10-5 M oestradiol-17/ showing
extensive necrosis of the alveolar epithelium and fibromuscular
stroma ( x 500).
also reduced the testosterone response to control levels but
treatment with 4 x 10- I M oestradiol-17/ remained more
inhibitory. Pre-treatment with the estramustine compounds
(4x 10 -5M) for 48h before the addition of 4x 10 -9
testosterone did not enhance the inhibitory actions of these
drugs, and oestradiol-17/3 remained the most potent inhibitor
of the testosterone response (Figure 6).
Histology Histologically, cultures treated with 4 x 10-7 M
testosterone alone or in combination with 4 x 10-M
Estracyt, Emcyt or estramustine in serum-free medium all
showed well maintained, actively secreting alveolar
epithelium. However, similar cultures treated with 4 x 10-7 M
testosterone and 4 x 10 M oestradiol-17/3 exhibited
extensive epithelial and stromal necrosis.
Cultures treated with only 4 x 10-9 M testosterone were
well-preserved (Figure 7A), but the addition of 4 x O- M
Estracyt (Figure 7B), Emcyt or estramustine caused epithelial
atrophy. However, treatment with 4 x 10- 7 M oestradiol-17p
also produced severe epithelial regression (Figure 7C) and
4 x 10- I M oestradiol-17# remained cytotoxic.
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Figure 5 Effects of 4 x 10-I M Estracyt (LS 299), Emcyt (LS
299Z), estramustine (LS 275) and oestradiol-17/3 (E2-17,B) on
4 x 10-9 M testosterone stimulated I-UdR uptake in serum-free
cultures of rat ventral prostate. Testosterone-free control cultures
are represented by *, medium only, and L, medium containing
the alcohol diluent (mean +s.e.; 16 explants/treatment group, 3
separate experiments). Dotted line indicates mean + s.e. of
stimulation index of testosterone only supplemented cultures.
Discussion
While several studies have demonstrated inhibitory effects of
Estracyt on prostatic DNA synthesis (Forsberg & Hoisaeter,
1975; Hoisaeter, 1975, 1976b, 1977), others have been unable
to distinguish the effect of Estracyt from that of oestradiol-
17/3 (Yamanaka et al., 1977; Wakisaka et al., 1979; Mistry et
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Figure 6 Proliferative responses of rat ventral prostate in
serum-free medium following treatment with 4 x 10 -5M Estracyt
(LS 299), Emcyt (LS 299Z), estramustine (LS 275) and
oestradiol-17, (E2-17,B) for the first 48 h and 4 x 10 -9 M testos-
terone during the final 48h of the culture. 'Control' represents
testosterone-free cultures (mean +s.e.; 16 explants/treatment
group, 3 separate experiments).
al., 1983). In the present study, treatment with 4 x10M
Estracyt, estramustine and oestradiol-17/3 in serum supple-
mented medium all had equally inhibitory effects on
4 x 10-6M testosterone induced I-UdR uptake, whereas in
serum-free medium only oestradiol-17/3 was effective in sup-
pressing the response to testosterone. The histological results
further demonstrated that the estramustine compounds had
no antiprostatic effect in serum-free medium, but were
cytotoxic in the presence of serum. In contrast, treatment
with oestradiol-17/ was markedly cytotoxic in serum free
medium, whereas it had an antiandrogenic effect causing
epithelial atrophy in the presence of serum. Thus, serum
appears to potentiate the antiprostatic activity of the estra-
mustine compounds, while it reduces the inhibitory action of
oestradiol-17#. The presence of steroid hormone binding
proteins in the serum supplement may be responsible for
eliminating the cytotoxic effect of oestradiol-17/3 and
reducing the magnitude of the inhibitory effect on 1-UdR
uptake by decreasing the concentration of free oestrogen in
the medium. Similarly, the presence of steroid binding
proteins may account for slight reductions in the stimulatory
effect of testosterone on I-UdR uptake in serum
supplemented cultures. However, the results did not indicate
that increasing serum concentrations further affected the
actions ofeither testosterone or oestradiol-17#.
In contrast to the present study, Hoisaeter (1975) found
that in organ cultures of rat ventral prostate maintained in
serum-supplemented medium (5% FCS) containing
4 x 10-6M testosterone and either 4 x 10- I M Estracyt or
oestradiol-177#, only Estracyt had a significantly inhibitory
effect on 3H-TdR uptake. Nevertheless, the histological
results were remarkably similar to the present study,
indicating that Estracyt had a pronounced cytotoxic effect
on rat ventral prostate cultured in serum-supplemented
medium while the retrogressive changes associated with
oestradiol-17/3 were less severe. Unlike the present study,
however, the morphology of cultures maintained in the
absence of exogenous testosterone was comparable to intact
tissue and did not demonstrate epithelial atrophy typical of
androgen deprivation (Hoisaeter, 1975). Moreover, Hoisaeter
(1975) was unable to demonstrate any stimulation of
3H-TdR uptake in cultures treated with only 4x 10-6M
.20p
Figure 7 Alveoli in explants of young adult rat ventral prostate
cultured for 4 days in serum-free medium containing 4 x 10 -9M
testosterone. H & E staining. (A) Explant treated with 4 x 10 -9 M
testosterone, showing well maintained alveolar epithelium
( x 500). (B) Explant treated with 4 x 10 9 M testosterone and
4 x 10-M Extracyt showing low cuboidal alveolar epithelium
( x 500). (C) Explant treated with 4 x 10-9 M testosterone and
4 x 10- oestradiol-17,B showing low cuboidal alveolar epithelium
(x500).
testosterone and this was attributed to a masking effect
caused by endogenous hormones present in the serum supple-
ment. While variations in the hormone content of different
batches of foetal calf serum (Esber et al., 1973) may be
responsible for these contrasting results, the present study
further suggests that serum supplementation obscures dif-
ferences between the effect of oestradiol-17/3 and its alkylated
analogues.
Subsequent investigations using only serum-free medium
showed that oestradiol-17/ remained consistently more
effective than any of the estramustine compounds in sup-
pressing testosterone induced I-UdR uptake. Oestradiol-17#
exhibited dose-related inhibitory effects on both 4 x 10'7 and
4 x 10 9M testosterone stimulated I-UdR uptake, whereas
the estramustine compounds were only inhibitory at
4 x 1-0 M in cultures treated with physiological concen-
trations of testosterone (i.e. 4 x 10 -9M). Pre-treatment (48h)
with the estramustine compounds did not enhance their
ability to suppress the testosterone response, and their
addition 48 h after testosterone reduced the magnitude of
the inhibitory response. The histological results further
demonstrated that treatment with 4 x 10 -9 M testosterone
and any of the estramustine compounds at 4 x 10- I M caused
epithelial atrophy, however lower concentrations of
oestradiol-17# produced comparable inhibition of I-UdR
uptake and similar histological changes. Thus, the anti-
androgenic effects of the estramustine compounds may be
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due to the release of some oestradiol-17/ from the hormone
cytotoxic complex. Although Hoisaeter (1975) did not detect
any hydrolysis of Estracyt by rat ventral prostate in organ
culture, more recently Symes & Milroy (1982) found that the
cleavage rate of estramustine by prostatic tissue in vitro is
low but it is nevertheless, dose dependent, being greater at
10-5 than 10-8M. The inhibitory effects described with
compounds in the range of 1O-9-1O-8 M would be in the
physiological range of concentrations. Steady state concen-
trations of estramustine in the plasma are of a similar range
to those used in these experiments (10-8 -1O-7 M) (Hartley-
Asp & Gunnarsson, 1982).
While the oestradiol-17,B released upon hydrolysis of
Estracyt probably contributes to the antiprostatic activity of
this drug (Sandberg, 1983), a purely oestrogenic mode of
action for Estracyt probably contributes to the antiprostatic
activity of this drug (Sandberg, 1983), a purely oestrogenic
mode of action for Estracyt has been discounted on evidence
of anti-tumour activity in oestrogen relapsed prostatic cancer
patients (Jonsson et al., 1977; Madajewicz et al., 1980;
Leistenschneider & Nagel, 1980) and in oestrogen resistant
animal tumours (Muntzing et al., 1979). In vitro studies of
hormone unresponsive prostatic cancer cells (DU 145)
further suggest that estramustine is the biologically active
form of Estracyt (Hartley-Asp & Gunnarsson, 1982; Hartley-
Asp, 1984), however recent organ culture studies of human
prostatic cancer tissue showed that DNA synthesis was
equally inhibited by oestradiol-17/3 and estramustine (Mistry
et al., 1983). Moreover, the present in vitro system indicates
that neither Estracyt nor its metabolite, estramustine, offer
any selective advantage over that of their carrier-hormone,
oestradiol-17/ in suppressing testosterone-induced DNA
synthesis in rat ventral prostate. Nevertheless, enhancement
in the antiprostatic acitivty of the estramustine compounds
in the presence of serum in vitro suggests that these drugs
require biological activation for maximum efficacy.
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